The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

Omvoh demonstrated 53% clinical remission and 46% endoscopic ... October 2023 approval as a first-in-class treatment for ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

"With Omvoh approved in both Crohn's disease and ulcerative colitis, more patients now have a treatment option that may ...